Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad gets $14.2 million for pathogen drug/diagnostic:

This article was originally published in Clinica

Executive Summary

Myriad Genetics has been awarded a five-year, $14.2m contract by the US National Institutes of Health for work that could lead to the development of products that focus on microorganisms and pathogens. The Salt Lake City, Utah firm says it will use its expertise to characterise pathogen-host protein interactions in an effort to discover targets for the next generation of vaccines, therapeutics and diagnostics. Protein interaction and validation data will be made available to the research and development community through the Proteomics Research Program Administrative Center. Myriad says it retains the rights to commercialise diagnostic and therapeutic targets discovered from the project.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel